Company intelligence / Profile preview

Lobo Genetics

Toronto, Ontario, Canada

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Lobo Genetics operates a commercial direct-to-consumer genetic testing platform that provides personalized insights into individual responses to cannabis and psychedelic drugs; no therapeutic clinical trial results are reported, as the offering is a diagnostic/genetic screening service rather than a drug product.

Therapeutic areas: Psychiatry
Modalities: Non-pharmacological therapyDeviceDiagnostics
Industry: Molecular Diagnostics

Partnerships

HaluGen Life Sciences (development of psychedelics genetic test)Alcanna / Nova Cannabis (retail partnership for cannabis genetic testing in Alberta)

Beyond the preview

Go deeper on Lobo Genetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lobo Genetics.

Explore the full profile